Sangamo Therapeutics Surges Ahead with FDA Approval Momentum

Sangamo Therapeutics shares are trading higher after the company announced FDA acceptance of a rolling Biologics License Application submission for ST-920 in Fabry Disease, highlighting its potential as a transformative treatment.